Overview
- Moderna, which reported results Friday, posted $389 million in first‑quarter revenue, led by $311 million from international markets versus $78 million in the U.S.
- The company recorded a GAAP loss of $3.40 per share that includes roughly $900 million tied to a March settlement with Genevant and Arbutus, and it lifted its 2026 cost‑of‑sales outlook to $1.8 billion.
- Management reaffirmed guidance for up to 10% revenue growth in 2026 and said sales should split about evenly between the U.S. and international markets.
- Executives said U.S. vaccine use has fallen after policy changes under Health Secretary Robert F. Kennedy Jr., so the company is leaning more on long‑term supply deals in the UK, Canada, and Australia.
- Beyond COVID, Moderna pointed to late‑stage work on a norovirus shot, an individualized cancer vaccine with Merck, and a therapy for propionic acidemia, and it awaits the FDA’s August 5 ruling on its mRNA flu shot after resolving a dispute over trial design.